Clinical Trial Update: An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 [Phase 2, Phase 3]

View source ↗

Summary

An extension study is evaluating the long-term safety, tolerability, and efficacy of Tividenofusp alfa (DNL310) in participants with mucopolysaccharidosis type …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Ii

Drugs mentioned

• Tividenofusp alfa (tividenofusp alfa)

Snippet

Sponsor: Denali Therapeutics Inc. | Conditions: Mucopolysaccharidosis II | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION